Recognition highlights the CRO’s global expansion strategy, sponsor-focused execution, and commitment to operational excellence.
LUND, S.E., May 14, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), today announced it has been named a finalist for the 2025 CRO Award for Excellence in Global Operations by Fierce Biotech. This honor celebrates the organizations driving innovation and impact through a global suite of clinical trial services, including full-service clinical development, functional service provision (FSP) models, and strategic resourcing.
“Being named a finalist for this prestigious award is a milestone moment for TFS and a tribute to the people behind our progress,” said Markus Granlund, CEO of TFS. “Our team has reimagined what a global CRO can be: focused, agile, and built around the therapeutic needs of our global partners and the lives of the patients we ultimately serve.””
Rooted in Sweden and operating across 50 countries, TFS has strategically expanded its global footprint while maintaining the personalized attention and flexibility of a mid-size partner. In the U.S., TFS’s presence was recently recognized with the 2025 Life Sciences Award from the Triangle Business Journal, affirming the company’s rising impact in one of the world’s leading research hubs.
The finalist distinction for this award underscores its ability to deliver operational excellence with global consistency, aligning regional expertise, high-performance teams, and a sponsor-first mindset to drive meaningful outcomes across continents. It also reflects TFS’s broader commitment to responsible growth, evident in its sustainability efforts, community partnerships, and people-first culture. With five consecutive EcoVadis Silver Ratings and over 20 philanthropic initiatives worldwide, TFS continues to expand its impact beyond trials and across its global footprint.
Under the guidance of new leadership, TFS has also embarked on a bold transformation of its global delivery model, introducing fully integrated, therapeutic-area teams that align all aspects of clinical development under a unified therapeutic focus. This model represents a natural evolution of the operational rigor and sponsor-aligned strategy that earned TFS this recognition. The result is a more synchronized, knowledge-rich delivery approach that aligns deeply with sponsor goals and patient needs.
“At TFS, global operations mean more than reach; they are defined by precision, accountability, and shared purpose,” said Granlund. “Being a finalist in this category affirms the strength of our model, the resilience of our people, and the trust our partners place in us every day.”
About TFS HealthScience
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 50 countries, TFS and its strategic partners provide tailored strategic resourcing solutions and clinical development services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness of a mid-sized CRO.
For more information, visit www.tfscro.com.
About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biopharma professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.